

HR 1669

Pharmacy Benefit Manager Transparency Act of 2005

Congress: 109 (2005–2007, Ended)

Chamber: House **Policy Area:** Law

Introduced: Apr 14, 2005

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 13, 2005) **Official Text:** https://www.congress.gov/bill/109th-congress/house-bill/1669

Sponsor

Name: Rep. Weiner, Anthony D. [D-NY-9]

Party: Democratic • State: NY • Chamber: House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Moran, Jerry [R-KS-1]	$R \cdot KS$		Apr 14, 2005
Rep. Boozman, John [R-AR-3]	$R \cdot AR$		Dec 8, 2005

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 13, 2005

Subjects & Policy Tags

Policy Area:

Law

Related Bills

No related bills are listed.

Pharmacy Benefit Manager Transparency Act of 2005 - Prohibits any pharmaceutical drug manufacturer from having a controlling interest in an entity that is a pharmacy benefit manager. Allows the Secretary of Health and Human Services to issue civil penalties for violations as necessary.

Prohibits pharmacy benefit managers from making drug interchanges: (1) to a drug with a greater cost; (2) without disclosure to the individual of the savings associated with the interchange; or (3) from a drug with generic equivalents to a drug without generic equivalents, unless the latter is lower in cost than each of the generic equivalents of the drug from which the prescription would be changed.

Requires pharmacy benefit managers to annually disclose all compensation received from drug manufacturers to the Antitrust Division of the Department of Justice (DOJ) and to the client plans of such manager.

Actions Timeline

- May 13, 2005: Referred to the Subcommittee on Health.
- Apr 14, 2005: Introduced in House
- Apr 14, 2005: Introduced in House
- Apr 14, 2005: Referred to the House Committee on Energy and Commerce.